Title |
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
|
---|---|
Published in |
Frontiers in oncology, May 2016
|
DOI | 10.3389/fonc.2016.00112 |
Pubmed ID | |
Authors |
Pranshu Bansal, Diaa Osman, Gregory N. Gan, George R. Simon, Yanis Boumber |
Abstract |
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | 11% |
United States | 1 | 11% |
Unknown | 7 | 78% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 56% |
Practitioners (doctors, other healthcare professionals) | 3 | 33% |
Scientists | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 46 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 17% |
Student > Master | 7 | 15% |
Student > Postgraduate | 6 | 13% |
Student > Ph. D. Student | 5 | 11% |
Student > Bachelor | 4 | 9% |
Other | 8 | 17% |
Unknown | 8 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 37% |
Agricultural and Biological Sciences | 8 | 17% |
Biochemistry, Genetics and Molecular Biology | 6 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
Computer Science | 1 | 2% |
Other | 3 | 7% |
Unknown | 7 | 15% |